Investments, Funding & Disinvestment

The partnership will begin with a study focused on assessing Mirai’s ability to predict breast cancer risk specifically in Japanese women using mammography images.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.

Morocco’s pledge is timely, as Gavi prepares to implement its next strategic phase, known as “Gavi 6.0,” which aims to protect 500 million children between 2026 and 2030

The funding will focus on preventing and managing diseases such as HIV/AIDS, tuberculosis (TB), and malaria, as well as improving maternal and child health, eradicating polio, strengthening disease surveillance, and enhancing preparedness for infectious disease outbreaks.

Regeneron is investing USD 150 million in equity and upfront payments to acquire half of the global development and commercialization rights for TSRA-196.

The closure announcement follows Valneva’s financial results for the first nine months of 2025, which revealed mixed performance.

AdipoLABs operates as a Ministry of Health (MOH)-registered medical device establishment under the Medical Device Authority (MDA), providing regulatory credibility and demonstrating commitment to quality and innovation.

The total USD20.9 million funding will be divided into two tranches, with the release of the second contingent on outcomes from the ongoing ‘SEALS’ phase 2 clinical trial.

The international event brings together leading experts and practitioners from around the world to share knowledge, advance modern surgical techniques, and shape the future of robotic surgery.

This new facility aims to help Liberia achieve WHO Maturity Level 3, a benchmark the country has sought for decades without success.